[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Daejeon St. Mary's hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644068","phase-4-efficacy-of-verciguat-in-tr-and-rv-failure-100644068",false,"NCT07668739","Efficacy of Verciguat in TR and RV Failure","Efficacy of Vericiguat in HFrEF Patients With Coexisting Severe Tricuspid Regurgitation and Right Heart Failure; Multicenter Pragmatic Randomized Controlled Trial","VERT-HF","Inclusion Criteria:\n\n1. Age more than 19 years old\n2. right ventricular malfunction confirmed with EKG data or cardiac MRI\n3. chronic heart failure with LVEF\\\u003C45%\n4. Patients Who administrated standard treatment of Heart Failur for over the 4 weeks\n5. NTproBNP \\>1000, NTproBNP \\>1600 with atrial fibrillation or The patient who recently experienced worsening heart failure(Recent hospitalization for worsening heart failure or outpatient administration of intravenous diuretics)\n6. Tricuspid regurgitation of greater than moderate severity was confirmed by echocardiogram\n7. Subject who provided voluntary informed consent to participate in the study\n8. Patients who have not been administered vericiguat within the last 6 months\n\nExclusion Criteria:\n\n1. Patients with a systolic blood pressure (SBP) \\\u003C 100 mmHg\n2. Patients currently treated with other sGC stimulators (including vericiguat) or phosphodiesterase-5 (PDE5) inhibitors\n3. Moderate-to-severe right ventricular (RV) failure requiring surgical intervention\n4. Patients who are currently pregnant or of childbearing potential","ALL","19 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if the drug vericiguat works to improve right heart function in patients with worsening heart failure who have reduced left ventricular function. It will also examine the effects of the drug on tricuspid regurgitation (TR) and overall clinical outcomes.\n\nThe main questions it aims to answer are:\n\nDoes vericiguat improve right ventricular (RV) function and reduce tricuspid regurgitation (TR)? Does vericiguat reduce the risk of major adverse cardiovascular events (MACE), such as heart failure hospitalizations and cardiovascular death? Does vericiguat improve participants' exercise capacity, quality of life, and renal function?\n\nResearchers have previously seen the benefits of vericiguat in the large-scale VICTORIA trial for worsening heart failure, and it is hypothesized that improvements in right heart function play a key role. This study aims to confirm these specific benefits.\n\nParticipants will:\n\nTake vericiguat as prescribed during the study period. Undergo echocardiograms at enrollment and at 9 months to assess right heart function.\n\nComplete questionnaires (KCCQ-12) and walking tests (6MWT) to evaluate quality of life and exercise capacity.\n\nProvide blood samples to monitor NTproBNP levels and renal function (creatinine).",[27,28],"HFrEF","Tricuspid Regurgitation (TR)",[27,30,31],"TR","Vericiguat","NOT_YET_RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":21},"2026-07-01",{"date":40,"type":21},"2028-05-31",{"name":42,"class":43},"Daejeon St. Mary's hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100637356","phase-4-1-or-6-months-of-dual-antiplatelet-therapy-after-drug-coated-balloon-angioplasty-for-de-novo-small-coronary-artery-disease-100637356","NCT07592507","1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease","1 or 6 Months of Dual Antiplatelet Therapy After Drug-Coated Balloon Angioplasty for De Novo Small Coronary Artery Disease: An Open-label, Randomized, Non-inferiority Trial","D-ONE","Inclusion Criteria:\n\n* 1)Adults aged 19 years or older 2)Subjects who have undergone drug-coated balloon (DCB) angioplasty 3) Subjects with stable angina, asymptomatic ischemia, and angiographically confirmed coronary lesions 4)Patients who have not undergone coronary intervention and whose coronary angiography demonstrates a reference vessel diameter between 2.0 mm and 3.0 mm, meeting all of the following conditions: No severe dissection corresponding to National Heart, Lung, and Blood Institute (NHLBI) grade C to F No reduction in coronary blood flow defined as TIMI flow grade \\\u003C 2 No residual stenosis ≥ 30% 5)Patients newly diagnosed with small-vessel coronary artery disease among those maintained on single antiplatelet therapy (SAPT) for at least 6 months after undergoing: de novo percutaneous coronary intervention (de novo PCI),in-stent restenosis PCI (ISR PCI), or percutaneous transluminal coronary angioplasty (PTCA) 6)Subjects who voluntarily agree to participate in this clinical study and provide written informed consent\n\nExclusion Criteria:\n\n* 1\\) Patients diagnosed with Acute Coronary Syndrome (ACS), including STEMI, NSTEMI, or Unstable Angina.\n\n  2\\) Patients undergoing concomitant Percutaneous Coronary Intervention (PCI) during the Drug-Coated Balloon (DCB) procedure.\n\n  3\\) Patients undergoing PCI for In-Stent Restenosis (ISR). 4) Patients with a diagnosis of active bleeding or coagulation disorder within 2 months prior to obtaining informed consent.\n\n  5\\) Patients who underwent surgery with moderate-to-high risk within 6 weeks prior to obtaining informed consent.\n\n  6\\) Patients with a history of intracerebral hemorrhage (ICH). 7) Patients with Hemoglobin \\\u003C 10 g\u002FdL or Platelet count \\\u003C 100 x 10³\u002Fmm³. 8) Patients unable to discontinue oral anticoagulation therapy (OAC). 9) Patients on long-term treatment with NSAIDs or COX-2 inhibitors (excluding aspirin).\n\n  10\\) Patients with a life expectancy of less than 1 year due to malignancy or other comorbidities.\n\n  11\\) Patients with moderate-to-severe hepatic impairment. 12) Patients at risk of symptomatic bradycardia (e.g., 2nd-degree Mobitz Type II block or 3rd-degree AV block).\n\n  13\\) Patients with dyspnea, such as those with Chronic Obstructive Pulmonary Disease (COPD).\n\n  14\\) Patients with intolerance or hypersensitivity to the investigational medicinal products.\n\n  15\\) Patients who participated in other clinical trials within 3 months prior to informed consent (excluding non-interventional observational studies).\n\n  16\\) Women who are pregnant or breastfeeding. 17) Patients with End-Stage Renal Disease (ESRD) on hemodialysis or peritoneal dialysis, or those who have undergone a kidney transplant.\n\n  18\\) Patients with rare hereditary metabolic disorders, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n\n  19\\) Any patient deemed unsuitable for participation in the clinical trial at the investigator's discretion.",{"count":54,"type":21},1484,[24],"1. Objective Objective: \\> The purpose of this study is to evaluate whether a short-term (1-month) dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) is non-inferior to the standard 6-month DAPT in patients undergoing Drug-Coated Balloon (DCB) angioplasty for de novo small coronary artery disease.\n\n   Methods: \\> This is an open-label, randomized, non-inferiority trial. Patients will be assigned to either 1 month or 6 months of DAPT after successful DCB treatment. The study will compare the incidence of Net Adverse Clinical Events (NACE)-a composite of cardiovascular death, myocardial infarction, target vessel revascularization, and major bleeding-between the two groups from 1 to 12 months post-procedure.\n2. Background Following percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is essential to prevent stent thrombosis and ischemic events. While short-duration DAPT (e.g., 4 weeks) has shown benefits in patients at high bleeding risk, evidence regarding the optimal DAPT duration specifically after Drug-Coated Balloon (DCB) angioplasty for small vessel disease remains insufficient. This study aims to fill this clinical gap by comparing 1-month versus 6-month DAPT strategies.\n\nPrimary Objective To demonstrate the non-inferiority of 1-month DAPT (followed by SAPT up to 12 months) compared to 6-month DAPT in terms of Net Adverse Clinical Events (NACE) occurring between 1 and 12 months post-randomization.\n\nSecondary Objectives To evaluate ischemic safety (CV death, MI, TLR). To assess bleeding safety (BARC type 2, 3, or 5). To analyze individual components of the primary composite endpoint, including all-cause death and stent thrombosis.",[58,59],"Stable Angina Pectoris","Coronary Artery Disease",[61,62,63,64,65,66,67],"DAPT","aspirin","clopidogrel","drug coated balloon","DCB","dual antiplatelet therapy","small vessel disease","2026-05-11",{"date":70,"type":36},"2026-05-18",{"date":72,"type":21},"2026-05",{"date":74,"type":21},"2032-02",{"name":42,"class":43},""]